Cantor Fitzgerald Forecasts Alumis FY2025 Earnings

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Alumis in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will post earnings per share of ($4.13) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.15) per share.

ALMS has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and issued a $26.00 price objective on shares of Alumis in a research report on Monday, January 6th. Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Finally, Robert W. Baird assumed coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $26.83.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $6.68 on Thursday. The stock’s 50 day moving average price is $8.33 and its 200-day moving average price is $10.56. Alumis has a twelve month low of $6.40 and a twelve month high of $13.53.

Institutional Investors Weigh In On Alumis

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in Alumis in the 4th quarter valued at $79,000. JPMorgan Chase & Co. bought a new position in shares of Alumis in the third quarter worth $191,000. Barclays PLC purchased a new stake in shares of Alumis in the third quarter worth $197,000. Geode Capital Management LLC purchased a new position in Alumis during the third quarter worth about $3,266,000. Finally, State Street Corp purchased a new position in Alumis during the third quarter worth about $866,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.